Free Trial
NASDAQ:TRML

Tourmaline Bio Q4 2024 Earnings Report

Tourmaline Bio logo
$16.28 +0.32 (+2.01%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$15.61 -0.67 (-4.14%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tourmaline Bio EPS Results

Actual EPS
-$0.86
Consensus EPS
-$0.91
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Tourmaline Bio Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tourmaline Bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Tourmaline Bio's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Tourmaline Bio Earnings Headlines

Tourmaline Bio Inc News (TRML) - Investing.com
TRML - Tourmaline Bio Inc Dividends - Morningstar
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
TRML - Tourmaline Bio Inc Executives - Morningstar
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio (NASDAQ:TRML) (NASDAQ:TRML) is a clinical-stage biopharmaceutical company focused on developing next-generation antibody therapeutics for oncology and immune-mediated diseases. The company’s proprietary glycoengineering platform is designed to optimize antibody effector functions and improve therapeutic indices by precisely modifying glycan structures. Headquartered in Cambridge, Massachusetts, Tourmaline Bio leverages cutting-edge research to advance a pipeline of novel monoclonal antibodies and antibody-drug conjugates aimed at addressing high unmet medical needs.

The company’s R&D strategy centers on enhancing antibody activity while minimizing off-target effects. By employing site-specific glycan remodeling, Tourmaline Bio seeks to bolster antibody-dependent cellular cytotoxicity and enhance tumor cell clearance. This platform approach supports both in-house candidate development and external partnerships, enabling collaborations with larger pharmaceutical companies to co-develop or out-license lead assets. The flexibility of the platform allows for rapid iteration and optimization across multiple therapeutic targets.

Tourmaline Bio’s pipeline features several preclinical and clinical-stage assets, including a bispecific antibody in Phase 1 development for solid tumors and an engineered anti-CD20 antibody for B-cell malignancies. The company has also initiated exploratory programs in autoimmune indications, where glycoengineered antibodies may offer improved safety profiles over conventional biologics. With manufacturing scaled through state-of-the-art CMC capabilities in North America and Europe, Tourmaline Bio maintains strategic partnerships to support global clinical development and eventual commercial readiness.

Founded in 2018 by a team of biochemists and immunologists, Tourmaline Bio is led by President and CEO Michael Scharpe, whose prior leadership roles include senior management positions at established biotech firms. The executive team is rounded out by Nancy Lee, Chief Financial Officer, and Dr. David Normoyle, Chief Scientific Officer, each bringing extensive experience in antibody drug discovery and corporate finance. Together, they guide Tourmaline Bio’s mission to translate innovative antibody engineering into transformative therapies for patients worldwide.

View Tourmaline Bio Profile

More Earnings Resources from MarketBeat